Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis.

Fendrick AM, Greenberg BP.

Osteopath Med Prim Care. 2009 Jan 6;3:1. doi: 10.1186/1750-4732-3-1.

PMID:
19126235
[PubMed]
Free PMC Article
2.

Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.

Rostom A, Moayyedi P, Hunt R; Canadian Association of Gastroenterology Consensus Group.

Aliment Pharmacol Ther. 2009 Mar 1;29(5):481-96. doi: 10.1111/j.1365-2036.2008.03905.x. Epub 2008 Nov 27.

PMID:
19053986
[PubMed - indexed for MEDLINE]
3.

Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.

Matheson AJ, Figgitt DP.

Drugs. 2001;61(6):833-65. Review.

PMID:
11398914
[PubMed - indexed for MEDLINE]
4.

The role of rofecoxib, a cyclooxygenase-2-specific inhibitor, for the treatment of non-cancer pain: a review.

Fine PG; Department of Anesthesiology, School of Medicine, University of Utah, Salt Lake City, 84108, USA. fine@aros.net.

J Pain. 2002 Aug;3(4):272-83.

PMID:
14622751
[PubMed]
5.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

JAMA. 2000 Sep 13;284(10):1247-55.

PMID:
10979111
[PubMed - indexed for MEDLINE]
6.

Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.

Scheiman JM, Hindley CE.

Clin Ther. 2010 Apr;32(4):667-77. doi: 10.1016/j.clinthera.2010.04.009. Review.

PMID:
20435236
[PubMed - indexed for MEDLINE]
7.

Valdecoxib: a review.

Chavez ML, DeKorte CJ.

Clin Ther. 2003 Mar;25(3):817-51. Review.

PMID:
12852704
[PubMed - indexed for MEDLINE]
8.
9.

Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):223-7.

PMID:
18084859
[PubMed - indexed for MEDLINE]
10.

Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Litalien C, Jacqz-Aigrain E.

Paediatr Drugs. 2001;3(11):817-58. Review.

PMID:
11735667
[PubMed - indexed for MEDLINE]
11.

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

Hochberg MC.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.

PMID:
12528069
[PubMed - indexed for MEDLINE]
12.

The David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environment.

Chan FK.

Am J Gastroenterol. 2008 Jan;103(1):221-7. Epub 2007 Sep 25.

PMID:
17900323
[PubMed - indexed for MEDLINE]
13.

Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.

Dajani EZ, Islam K.

J Physiol Pharmacol. 2008 Aug;59 Suppl 2:117-33. Review.

PMID:
18812633
[PubMed - indexed for MEDLINE]
Free Article
14.

Recent developments in the treatment of osteoarthritis with NSAIDs.

Argoff CE.

Curr Med Res Opin. 2011 Jul;27(7):1315-27. doi: 10.1185/03007995.2011.568058. Epub 2011 May 12. Review.

PMID:
21561395
[PubMed - indexed for MEDLINE]
15.

Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors.

Schnitzer TJ.

Clin Ther. 2001 Mar;23(3):313-326; discussion 311-2. Review.

PMID:
11318071
[PubMed - indexed for MEDLINE]
16.

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.

Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, Rostom A, Symmons D.

Health Technol Assess. 2006 Oct;10(38):iii-iv, xi-xiii, 1-183. Review.

PMID:
17018227
[PubMed - indexed for MEDLINE]
Free Article
17.

Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.

Chan FK, Abraham NS, Scheiman JM, Laine L; First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.

Am J Gastroenterol. 2008 Nov;103(11):2908-18. doi: 10.1111/j.1572-0241.2008.02200.x. Epub 2008 Oct 1.

PMID:
18853980
[PubMed - indexed for MEDLINE]
18.
19.

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.

Circulation. 2001 Nov 6;104(19):2280-8.

PMID:
11696466
[PubMed - indexed for MEDLINE]
Free Article
20.

Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S392-400.

PMID:
12416789
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk